Enanta Q3 loss $1.86/diluted share; revenue $18.9M; positive Phase 1 RSV data

ENANTA PHARMACEUTICALS INC

2023-Q3 EPS reported -$5.05 revenue$60,272,000

Net loss $39.1M ($1.86/diluted) vs. $31.7M ($1.53) in prior-year Q3; revenue $18.9M down from $19.5M.
Cash and marketable securities $392.5M at June 30; sold 54.5% of future royalty to OMERS for $200M.
Positive Phase 1 data for RSV L-protein inhibitor EDP-323; Phase 2 human challenge study expected early Q4 2023.
Updated FY2023 guidance: R&D $165M-$175M; G&A $50M-$55M; royalty portion to OMERS from Q4 onward.
Phase 2 COVID EDP-235 showed 1.0 log viral load drop in nucleocapsid-negative patients treated within 3 days.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ENANTA PHARMACEUTICALS INC reported fiscal third quarter ended June 30, 2023 results: revenue $18.9 million, net income Net loss for the three months ended June 30, 2023 was $39.1 million, or a loss of $1.86 per diluted common share, EPS $1.86 per diluted common share. Guidance reaffirmed.

Period: fiscal third quarter ended June 30, 2023
Revenue: $18.9 million
Net income: Net loss for the three months ended June 30, 2023 was $39.1 million, or a loss of $1.86 per diluted common share
EPS: $1.86 per diluted common share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Expect to Initiate Phase 2 Human Challenge Study in Early 4Q 2023. • Cash and Marketable Securities Totaled $392.5 Million at June 30, 2023 • Royalty Revenue for the Quarter was $18.9 Million WATERTOWN, Mass., Aug. 7, 2023 – Enanta Pharmaceuticals, Inc . (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral

View on SEC.gov

171 earnings releases filed in the last 30 days. Browse all earnings releases →

ENANTA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0000950170-23-039051

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.